Dexcom Super Bowl DTC; Pfizer Q4 and FY ’20 Earnings Update
Two diabetes-related news items have been observed: Dexcom announced the debut of its first-ever Super Bowl commercial; and Pfizer hosted its Q4 ’20 earnings call, commenting on its oral GLP-1 pipeline developments. Below, FENIX provides highlights and insights for the respective news items, including thoughts on how the Dexcom Super Bowl commercial signals that Dexcom is ready to move on the CGM mass market opportunity.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.